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In this issue of Cell Stem Cell, Zaruba et al. (2009) describe a pharmacoregenerative strategy for myocardial
infarction. Using G-CSF to release progenitors from bone marrow and protease inhibition to prevent degra-
dation of the homing signal, SDF-1, the authors achieve increased recruitment to the heart and improved
heart function.Patients who present with heart failure
exhibit a 5 year mortality comparable
to many malignancies, and yet, with
the exception of heart transplantation,
currently available therapies only delay
disease progression (Stewart et al.,
2001). Regenerative medicine, on the
other hand, holds the promise of func-
tional restoration by replenishing cardio-
myocytes and blood vessels. Thus, it’s
not surprising that stem cell therapies for
heart disease have generated enormous
excitement in both the scientific and lay
communities because of a perceived
potential for complete tissue repair.
Recent descriptions of resident adult
cardiac precursor populations present
new opportunities to harness the endoge-
nous regenerative potential without
exogenous delivery of stem cells (Segers
and Lee, 2008). In the current issue of
Cell Stem Cell, Zaruba and colleagues
describe such a strategy (Zaruba et al.,
2009). By combining the stem cell-mobi-
lizing properties of granulocyte colony-
stimulating factor (G-CSF) with a specific
protease inhibitor to increase cardiac
levels of the chemokine, stromal cell-
derived factor, type I (SDF-1), the authors
stimulated endothelial progenitor recruit-
ment to the heart after myocardial infarc-
tion (MI), which ultimately led to the gener-
ation of new blood vessels, improved
cardiac function, and increased survival.
G-CSF for stem cell mobilization, the
first component of the authors’ strategy,
is widely used to mobilize hematopoietic
stem cells from the bone marrow into
circulation prior to peripheral harvest as
a component of autologous stem cell
transplantation protocols. These stem
cell-mobilizing properties provided a ratio-nale for the administration of G-CSF after
MI, but thus far outcomes in human
studies have not been substantially
improved (Abdel-Latif et al., 2008).
Despite demonstrating a modest antia-
poptotic effect with G-CSF alone, the
marginal benefits of G-CSF monotherapy
in the study by Zaruba and colleagues are
consistent with this cumulative clinical
experience. The authors found, however,
that the addition of a homing signal direct-
ing G-CSF-mobilized stem cells to the site
of injury resulted in successful tissue
regeneration (Figure 1).
SDF-1 represents a rational candidate
to recruit circulating progenitors to sites
of ischemic injury because its production
is stimulated by hypoxia and it functions
as a chemoattractant for an array of
precursor cells, including bone marrow-
derived endothelial progenitors (Smart
and Riley, 2008). For instance, impaired
recruitment of circulating endothelial
progenitors to wounds in diabetic mice
can be overcome by the local administra-
tion of SDF-1, resulting in improved
wound healing (Gallagher et al., 2007). A
potential limitation to the therapeutic
activity of SDF-1 is its sensitivity to
cleavage by a number of proteases
including CD26/dipeptidylpeptidase IV
(DPP-IV) (De La Luz Sierra et al., 2004).
However, delivery of a protease-resistant
form of SDF-1 directly into the infarcted
heart led to both recruitment of CXCR4-
expressing progenitor cells and an
improvement in heart function (Segers
et al., 2007), suggesting that preventing
proteolytic cleavage of SDF-1 could be
therapeutically beneficial.
In their current study, the authors
describe a noninvasive method of modu-Cell Stem Clating SDF-1 within the heart by systemi-
cally inhibiting the action of DPP-IV with
a small molecule called Diprotin A (Zaruba
et al., 2009). As anticipated, the authors
observed that this approach resulted in
reduced DPP-IV activity in the heart after
MI. Notably, the DPP-IV activity in the
serum was not affected, perhaps explained
by the presence of a broad range of
enzymes with DPP-IV-like activity in serum.
To demonstrate that DPP-IV inhibition
specifically increased levels of active
SDF-1 in the heart, the authors exposed re-
combinant SDF-1 to heart homogenates
from DPP-IV null and wild-type mice, and
using mass spectroscopy demonstrated
preservation of the active, noncleaved
SDF-1 form in DPP-IV null samples. This
finding suggests that systemic DPP-IV inhi-
bition may be sufficient to increase the
active form of SDF-1 within the heart, effec-
tivelycreating a local chemotactic gradient.
The authors then demonstrate that
combining G-CSF therapy with DPP-IV
inhibition led to both endothelial progen-
itor mobilization into the blood stream
and homing to the heart. In addition to
expressing cell-surface markers (CD34+/
CD45+) suggesting a predominance of
endothelial progenitors, which are distinct
from other bone marrow populations like
mesenchymal stem cells (Belema-Bedada
et al., 2008), recruited cells also showed
increased expression of the SDF-1
receptor, CXCR4.The concomitant admin-
istration of AMD3100, a selective CXCR4
inhibitor, reversed endothelial progenitor
infiltration of the heart after MI, suggesting
that their migration is dependent on an
intact SDF-1-CXCR4 homing axis.
Mice treated with combined G-CSF
therapy and DPP-IV inhibition hadell 4, April 3, 2009 ª2009 Elsevier Inc. 277
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PreviewsFigure 1. Synergism of G-CSF Therapy with Inhibition of Proteolytic Degradation of SDF-1
Results in Progenitor Recruitment to the Heart after Myocardial Infarction
(Left) With G-CSF monotherapy, mobilized progenitors do not receive a homing signal to guide migration
to the heart. (Right) Inhibition of proteolytic cleavage of SDF-1, in concert with G-CSF therapy, restores
progenitor homing.increased neovascularization within the
infarct border zone compared to control
groups. Importantly, the authors also
found that combined treatment signifi-
cantly reduced postinfarct remodeling,
improved cardiac function, and extended
survival. Taken together, the improve-
ment in both cardiac function and survival
is likely attributable to pharmacologically
stimulated endothelial progenitor recruit-
ment and vascular regeneration by activa-
tion of the SDF-1/CXCR4 axis.278 Cell Stem Cell 4, April 3, 2009 ª2009 ElWhile this study achieves therapeutic
induction of a local chemotactic signal
and the recruitment of a progenitor popu-
lation without employing invasive delivery
or an exogenously prepared cell prepara-
tion, the study also underscores the
challenges facing pharmacologic regen-
erative strategies. The recruitment of
endogenous progenitors to injured tissue
requires a sequence of coordinated inter-
actions between progenitors and their
diverse biological environments. Progeni-sevier Inc.tors must first respond to a stimulatory
signal by exiting their niche, whether that
niche is located in bone marrow or within
the injured tissue itself. The efflux of
progenitors into the circulation must be
complemented by homing signals direct-
ing their infiltration into the target tissue.
Finally, local signals may be necessary
to direct cells to complete their migration
and participate in the repair process by
differentiating and becoming functionally
integrated. The study by Zaruba and
colleagues may explain the relative inef-
fectiveness of G-CSF monotherapy in
the absence of additional therapeutic
interventions aimed at establishing local
chemotactic signaling mechanisms.
While this study brings into sharp focus
the challenge of developing pharmaco-
logical regeneration strategies, it also
demonstrates the potential and impor-
tance of understanding stem cell traf-
ficking through circulation and within
injured tissues (Karp and Teo, 2009).
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